PREVENT: PRobiotics for EVEry Newborn Trial

Sponsor
The Hospital for Sick Children (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04537494
Collaborator
(none)
30
2
13

Study Details

Study Description

Brief Summary

The aim of the study is to compare prevention (oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks) with treatment-as-needed (supplementation with the probiotic L. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age). This is a single site pilot study to assess feasibility for a full trial.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: L. reuteri
N/A

Detailed Description

One in five infants experience colic, defined as recurrent and prolonged episodes of crying and fussing with no obvious cause in healthy infants less than 5 months of age. There is evidence to support the role of the probiotic L. reuteri for treatment of colic in breastfed babies and for prevention of colic. However, these two options (prevention vs treatment-as-needed) have not been previously compared head-to-head. The study aims determine if oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks (prevention) is superior to treatment-as-needed, as measured by daily cry/fuss duration at 6 and 12 weeks of age.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Prevention
Official Title:
PREVENT: PRobiotics for EVEry Newborn vs Treatment-as-Needed Comparative Effectiveness Trial
Anticipated Study Start Date :
Apr 1, 2021
Anticipated Primary Completion Date :
Nov 1, 2021
Anticipated Study Completion Date :
May 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Prevention

Oral supplementation with the probiotic L. reuteri administered to every newborn within the first week of life for 12 weeks

Dietary Supplement: L. reuteri
Probiotic
Other Names:
  • BioGaia
  • Other: Treatment-as-needed

    Supplementation with the probiotic L. reuteri after randomization, to infants who develop excessive cry/fuss up to 12 weeks of age

    Dietary Supplement: L. reuteri
    Probiotic
    Other Names:
  • BioGaia
  • Outcome Measures

    Primary Outcome Measures

    1. Combined infant daily cry/fuss duration [Baseline]

      The primary outcome will be infant daily cry/fuss duration (combined cry and fuss in minutes) measured using the modified Baby's Day Diary over a 48 hour period.

    2. Combined infant daily cry/fuss duration [6 weeks]

      The primary outcome will be infant daily cry/fuss duration (combined cry and fuss in minutes) measured using the modified Baby's Day Diary over a 48 hour period.

    3. Combined infant daily cry/fuss duration [12 weeks]

      The primary outcome will be infant daily cry/fuss duration (combined cry and fuss in minutes) measured using the modified Baby's Day Diary over a 48 hour period.

    Secondary Outcome Measures

    1. Infant daily cry duration [Baseline]

      Daily cry duration will be examined separately

    2. Infant daily cry duration [6 weeks]

      Daily cry duration will be examined separately

    3. Infant daily cry duration [12 weeks]

      Daily cry duration will be examined separately

    4. Infant daily fuss duration [Baseline, 6 and 12 weeks of age]

      Daily fuss duration will be examined separately

    5. Infant daily fuss duration [Baseline]

      Daily fuss duration will be examined separately

    6. Infant daily fuss duration [6 weeks]

      Daily fuss duration will be examined separately

    7. Infant colic [12 weeks]

      Daily cry/fuss of at least 180 minutes

    8. Infant daily sleep duration [Baseline]

      Sleep duration will be measured objectively using actigraphy worn around the infant's ankle over a sock.

    9. Infant daily sleep duration [6 weeks]

      Sleep duration will be measured objectively using actigraphy worn around the infant's ankle over a sock.

    10. Infant daily sleep duration [12 weeks]

      Sleep duration will be measured objectively using actigraphy worn around the infant's ankle over a sock.

    11. Parent (female and male) mental health [Baseline]

      Mental health will be measured using the Edinburgh Postnatal Depression Scale, a validated 10-item screening questionnaire. Scores range between 0 and 30 and higher scores mean worse outcome.

    12. Parent (female and male) mental health [6 weeks]

      Mental health will be measured using the Edinburgh Postnatal Depression Scale, a validated 10-item screening questionnaire. Scores range between 0 and 30 and higher score means worse outcome.

    13. Parent (female and male) mental health [12 weeks]

      Mental health will be measured using the Edinburgh Postnatal Depression Scale, a validated 10-item screening questionnaire. Scoring is between o and 30 and higher score means worse outcome.

    14. Parent (female and male) fatigue [Baseline]

      Fatigue will be measured using a validated Fatigue Visual Analogue Scale. Scores will range between 0 and 180, higher score means worse outcome

    15. Parent (female and male) fatigue [6 weeks]

      Fatigue will be measured using a validated Fatigue Visual Analogue Scale. Scores will range between 0 and 180, higher score means worse outcome.

    16. Parent (female and male) fatigue [12 weeks]

      Fatigue will be measured using a validated Fatigue Visual Analogue Scale. Scores will range between 0 and 180, higher score means worse outcome

    17. Gut microbial composition, diversity and function [Baseline]

      Microbial composition, diversity and function will be measured in infant fecal samples.

    18. Gut microbial composition, diversity and function [6 weeks]

      Microbial composition, diversity and function will be measured in infant fecal samples.

    19. Gut microbial composition, diversity and function [12 weeks]

      Microbial composition, diversity and function will be measured in infant fecal samples.

    20. Adverse effects - digestive upset [8 weeks]

      Number of participants with occurrences of digestive upset (e.g., diarrhea), in the Baby's Day Diary

    21. Adverse effects - digestive upset [16 weeks]

      Number of participants with occurrences of digestive upset (e.g., diarrhea), in the Baby's Day Diary

    22. Adverse effects - growth/length [8 weeks]

      Infant growth (length) will be measured at scheduled health supervision visits

    23. Adverse effects - growth/weight [8 weeks]

      Infant growth (weight) will be measured at scheduled health supervision visits

    24. Adverse effects - growth/head circumference [8 weeks]

      Infant growth (head circumference) will be measured at scheduled health supervision visits

    25. Adverse effects - growth/length [16 weeks]

      Infant growth (length) will be measured at scheduled health supervision visits

    26. Adverse effects - growth/weight [16 weeks]

      Infant growth (weight) will be measured at scheduled health supervision visits

    27. Adverse effects - growth/head circumference [16 weeks]

      Infant growth (head circumference) will be measured at scheduled health supervision visits

    28. Health services utilization [Baseline]

      Frequency of assessments

    29. Health services utilization [6 weeks]

      Frequency of assessments

    30. Health services utilization [12 weeks]

      Frequency of assessments

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    1 Day to 7 Days
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    1. 1 to 7 days of age

    2. term (37 to 41 weeks)

    3. breast or formula fed

    4. birth weight > 2500 grams

    5. parental consent

    Exclusion Criteria:
    1. congenital or other medical disorders

    2. parents unable to communicate in English or French

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • The Hospital for Sick Children

    Investigators

    • Principal Investigator: Patricia Parkin, MD, The Hospital for Sick Children
    • Principal Investigator: Patricia Li, MD, The Research Institute of the McGill University Health Centre

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Patricia Parkin, Professor, Senior Associate Scientist, Staff Pediatrician, The Hospital for Sick Children
    ClinicalTrials.gov Identifier:
    NCT04537494
    Other Study ID Numbers:
    • 1000064700
    First Posted:
    Sep 3, 2020
    Last Update Posted:
    Feb 12, 2021
    Last Verified:
    Feb 1, 2021
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Patricia Parkin, Professor, Senior Associate Scientist, Staff Pediatrician, The Hospital for Sick Children
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Feb 12, 2021